HRP20110193T1 - Inhibitor hcv nukleozida - Google Patents
Inhibitor hcv nukleozida Download PDFInfo
- Publication number
- HRP20110193T1 HRP20110193T1 HR20110193T HRP20110193T HRP20110193T1 HR P20110193 T1 HRP20110193 T1 HR P20110193T1 HR 20110193 T HR20110193 T HR 20110193T HR P20110193 T HRP20110193 T HR P20110193T HR P20110193 T1 HRP20110193 T1 HR P20110193T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- group
- hydrogen
- hcv
- methyl
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 239000001257 hydrogen Substances 0.000 claims abstract 11
- 150000002431 hydrogen Chemical class 0.000 claims abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract 5
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical group 0.000 claims abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 239000001177 diphosphate Substances 0.000 claims abstract 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims abstract 2
- 235000011180 diphosphates Nutrition 0.000 claims abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims abstract 2
- 150000004712 monophosphates Chemical class 0.000 claims abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract 2
- 239000001226 triphosphate Substances 0.000 claims abstract 2
- 235000011178 triphosphate Nutrition 0.000 claims abstract 2
- -1 triphosphate ester Chemical class 0.000 claims abstract 2
- 241000711549 Hepacivirus C Species 0.000 claims 8
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 229940122604 HCV protease inhibitor Drugs 0.000 claims 1
- 229940121759 Helicase inhibitor Drugs 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 229940122488 Primase inhibitor Drugs 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229940125777 fusion inhibitor Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj formule Inaznačen time što: R1, R2 i R3 nezavisno su izabrani iz grupe koju čine vodik, COR4, C(=O)OR4 i C(=O)CHR5NHR6; ili R1 i R3 su H i R2 je monofosfatni, difosfatni ili trifosfatni ester; R4 nezavisno je izabran iz grupe koju čine (a) C1-18 nerazgranati ili granati alkil, (b) C1-18 haloalkil, (c) C3-8 cikloalkil, (d) C1-10 heteroalkil i (e) fenil, pri čemu je navedeni fenil izborno supstituiran sa jednom do tri grupe nezavisno izabrane iz grupe koju čine C1-3 alkil, C1-3 alkoksi, halogen, cijano ili nitro; R5 je vodik, C1-10 alkil, fenil ili C1-3 fenilalkil, pri čemu je navedeni fenil izborno supstituiran sa jednom do tri grupe koje su nezavisno izabrane iz grupe koju čine halogen, hidroksid, C1-3 alkoksi, C1-3 alkil, cijano i nitro; R6 je vodik ili C1-6 alkoksi; ili, njegove kisele adicijske soli. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Spoj formule I
[image]
naznačen time što:
R1, R2 i R3 nezavisno su izabrani iz grupe koju čine vodik, COR4, C(=O)OR4 i C(=O)CHR5NHR6; ili R1 i R3 su H i R2 je monofosfatni, difosfatni ili trifosfatni ester;
R4 nezavisno je izabran iz grupe koju čine (a) C1-18 nerazgranati ili granati alkil, (b) C1-18 haloalkil, (c) C3-8 cikloalkil, (d) C1-10 heteroalkil i (e) fenil, pri čemu je navedeni fenil izborno supstituiran sa jednom do tri grupe nezavisno izabrane iz grupe koju čine C1-3 alkil, C1-3 alkoksi, halogen, cijano ili nitro;
R5 je vodik, C1-10 alkil, fenil ili C1-3 fenilalkil, pri čemu je navedeni fenil izborno supstituiran sa jednom do tri grupe koje su nezavisno izabrane iz grupe koju čine halogen, hidroksid, C1-3 alkoksi, C1-3 alkil, cijano i nitro;
R6 je vodik ili C1-6 alkoksi; ili,
njegove kisele adicijske soli.
2. Spoj prema patentnom zahtjevu 1, naznačen time što su svako R1, R2 i R3 - vodik.
3. Spoj prema patentnom zahtjevu 1, naznačen time što su svako R1, R2 i R3 nezavisno vodik, COR4 ili C(=O)OR4, pri čemu je R4 nerazgranati ili granati C1-10 alkil.
4. Spoj prema patentnom zahtjevu 1, naznačen time što, R1 je vodik, R2 i R3 su COR4 i R4 je nerazgranati ili granati C1-10 alkil; ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema patentnom zahtjevu 4, naznačen time što je svaka R4 grupa ista i izabrana iz grupe koju čine metil, etil, i-propil ili t-butil.
6. Spoj prema patentnom zahtjevu 1, naznačen time što je obilježeno kao ,5’-O-bis(izobutiril)-4’-azido-2’-β-C-metil-2’-deoksicitidin:
[image]
7. Spoj prema patentnom zahtjevu 1, naznačen time što su R1 i R3 vodik, R2 je izabran iz grupe koju čine COR4, C(=O)OR4 i COCH(R5)NHR6.
8. Spoj prema patentnom zahtjevu 7, naznačen time što, R2 je COCH(R5)NHR6, R5 je izo-propil, izo-butil ili sek-butil i R6 je vodik, poželjno pri čemu R5 ima stereokemiju L-aminokiseline.
9. Spoj prema patentnom zahtjevu 7, naznačen time što, R2 je COR4, pri čemu, R4 je C1-10 nerazgranati ili granati alkil.
10. Spoj prema patentnom zahtjevu 1, naznačen time što je izabran iz grupe koju čine
3’,5’-O-bis(izobutiril)-4’-azido-2’-β-C-metil-2’-deoksicitidin,
,5’-O-bis(L-valinil)-4’-azido-2’-β-C-metil-2’-deoksicitidin,
4’-Azido-3’-O-(L-valinil)-2’-β-C-metil-2’-deoksicitidin,
4’-Azido-3’-O-izobutiril -2’-β-C-metil-2’-deoksicitidin,
5’-O-(L-valinil)-4’-azido-2’-β-C-metil-2’-deoksicitidin,
5’-O-izobutiril -4’-azido-2’-β-C-metil-2’-deoksicitidin;
ili njegova farmaceutski prihvatljiva sol.
11. Primjena spoja prema bilo kojem od patentnih zahtjeva 1 do 10, naznačena time što se koristi u proizvodnji lijeka za liječenje bolesti posredovane preko virusa hepatitisa C (HCV).
12. Primjena prema patentnom zahtjevu 11, naznačena time što režim liječenja ili lijek dalje sadrže najmanje jedan modulator imunogenog sistema i/ili najmanje jedno antivirusno sredstvo koje inhibira replikaciju HCV-a.
13. Primjena prema patentnom zahtjevu 12, naznačena time što je modulator imunogenog sistema interferon, interleukin, faktor nekroze tumora ili faktor stimulacije kolonija.
14. Primjena prema patentnom zahtjevu 13, naznačena time što je modulator imunogenog sistema interferon ili kemijski derivatizirani interferon.
15. Primjena prema patentnom zahtjevu 12, naznačena time što režim liječenja ili lijek dalje sadrže najmanje jedno različito antivirusno sredstvo.
16. Primjena prema patentnom zahtjevu 15, naznačena time što je antivirusni spoj izabran iz grupe koju čine inhibitor HCV proteaze, drugi nukleozidni inhibitor HCV polimeraze, ne-nukleozidni inhibitor HCV polimeraze, inhhibitor HCV helikaze, inhibitor HCV primaze i inhibitor HCV fuzije.
17. Farmaceutska kompozicija naznačena time što sadrži terapeutski efikasnu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 10 pomiješanu sa najmanje jednim farmaceutski prihvatljivim nosačem, razblaživačem ili inertnim puniteljem.
18. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, što se koristi za primjenu kao lijek.
19. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što se koristi za primjenu u liječenju bolesti posredovane preko virusa hepatitisa C (HCV).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85092606P | 2006-10-10 | 2006-10-10 | |
| PCT/EP2007/060557 WO2008043704A1 (en) | 2006-10-10 | 2007-10-04 | Hcv nucleoside inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110193T1 true HRP20110193T1 (hr) | 2011-05-31 |
Family
ID=38925483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110193T HRP20110193T1 (hr) | 2006-10-10 | 2011-03-16 | Inhibitor hcv nukleozida |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US7666856B2 (hr) |
| EP (2) | EP2084175B1 (hr) |
| JP (2) | JP2010505902A (hr) |
| KR (1) | KR20090078347A (hr) |
| CN (2) | CN101979397B (hr) |
| AP (1) | AP2009004812A0 (hr) |
| AT (1) | ATE493428T1 (hr) |
| AU (1) | AU2007306405A1 (hr) |
| BR (1) | BRPI0719258A2 (hr) |
| CA (1) | CA2665049C (hr) |
| CO (1) | CO6180441A2 (hr) |
| CR (1) | CR10789A (hr) |
| CY (1) | CY1111342T1 (hr) |
| DE (1) | DE602007011658D1 (hr) |
| DK (1) | DK2084175T3 (hr) |
| EA (1) | EA018935B1 (hr) |
| ES (2) | ES2358853T3 (hr) |
| GT (1) | GT200900069A (hr) |
| HK (2) | HK1137459A1 (hr) |
| HN (1) | HN2009000614A (hr) |
| HR (1) | HRP20110193T1 (hr) |
| IL (1) | IL197907A0 (hr) |
| MX (1) | MX2009003452A (hr) |
| MY (1) | MY145314A (hr) |
| NO (1) | NO20091834L (hr) |
| NZ (1) | NZ575889A (hr) |
| PL (2) | PL2084175T3 (hr) |
| PT (1) | PT2084175E (hr) |
| RS (1) | RS51643B (hr) |
| SI (1) | SI2084175T1 (hr) |
| WO (1) | WO2008043704A1 (hr) |
| ZA (1) | ZA200902496B (hr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2358853T3 (es) * | 2006-10-10 | 2011-05-16 | Medivir Ab | Inhibidor nucleosídico de vhc. |
| CN100532388C (zh) * | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| TW201012814A (en) | 2008-07-01 | 2010-04-01 | Centocor Ortho Biotech Products L P | Cyclopropyl polymerase inhibitors |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| TW201023858A (en) * | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
| EP2166016A1 (en) | 2008-09-18 | 2010-03-24 | Centocor Ortho Biotech Products L.P. | Phosphoramidate Derivatives of Nucleosides |
| PA8852101A1 (es) | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
| DE102009028015A1 (de) * | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Mittel zur Behandlung von Hepatitis C-Infektionen |
| AU2010302971B2 (en) | 2009-09-29 | 2014-05-01 | Janssen Products, L.P. | Phosphoramidate derivatives of nucleosides |
| WO2011128378A1 (en) | 2010-04-13 | 2011-10-20 | Janssen Pharmaceuticals, Inc. | Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside |
| WO2012040124A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| EA025341B1 (ru) | 2010-09-22 | 2016-12-30 | Алиос Биофарма, Инк. | Замещенные аналоги нуклеотидов |
| JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| TW201331221A (zh) | 2011-10-14 | 2013-08-01 | Idenix Pharmaceuticals Inc | 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物 |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
| EA031301B1 (ru) | 2012-05-22 | 2018-12-28 | Иденикс Фармасьютикалз Ллс | D-аминокислотные химические соединения для лечения заболеваний печени |
| US9109001B2 (en) | 2012-05-22 | 2015-08-18 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| EP2861611B1 (en) | 2012-05-25 | 2016-07-13 | Janssen Sciences Ireland UC | Uracyl spirooxetane nucleosides |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| MX353422B (es) | 2012-10-08 | 2018-01-12 | Idenix Pharmaceuticals Llc | Análogos de 2'-cloronucleósido para infección por vhc. |
| EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014100505A1 (en) * | 2012-12-21 | 2014-06-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
| US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
| WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
| WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| UA117375C2 (uk) * | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
| US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6339752A (ja) | 1986-08-02 | 1988-02-20 | Kawada Tekko Kk | インデツクス装置 |
| SE8701605D0 (sv) | 1987-04-16 | 1987-04-16 | Astra Ab | Novel medicinal compounds |
| DE3715666A1 (de) | 1987-05-11 | 1988-11-24 | Kodak Ag | Kassettenentlade- und beladegeraet |
| GB8712115D0 (en) | 1987-05-22 | 1987-06-24 | Hoffmann La Roche | Pyrimidine derivatives |
| US5246924A (en) | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
| SE8802173D0 (sv) | 1988-06-10 | 1988-06-10 | Astra Ab | Pyrimidine derivatives |
| SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
| NZ231444A (en) * | 1988-11-21 | 1992-09-25 | Syntex Inc | 2'-deoxy-4'-azido-substituted nucleosides and medicaments |
| US5034518A (en) | 1989-05-23 | 1991-07-23 | Southern Research Institute | 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides |
| WO1991015470A1 (en) | 1990-03-30 | 1991-10-17 | Eastman Kodak Company | Alcohol-ester separation by reaction with acetate |
| AU7623991A (en) * | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
| IT1249732B (it) | 1991-11-26 | 1995-03-09 | Angeletti P Ist Richerche Bio | Oligonucleotidi antisenso. |
| US5418151A (en) | 1992-08-07 | 1995-05-23 | Genencor International, Inc. | Regio-selective process for resolution of carbohydrate monoesters |
| US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| DK1058686T3 (da) | 1998-02-25 | 2007-03-05 | Univ Emory | 2'-fluornukleosider |
| DE69925918T2 (de) | 1998-07-27 | 2006-05-11 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Diketosäure-derivate als hemmstoffe von polymerasen |
| CN1325309A (zh) | 1998-08-21 | 2001-12-05 | 维洛药品公司 | 用于治疗或预防病毒感染和相关疾病的化合物、组合物和方法 |
| WO2000013708A1 (en) | 1998-09-04 | 2000-03-16 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| EP1115286A4 (en) | 1998-09-25 | 2003-07-23 | Viropharma Inc | METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM |
| DE60005502T2 (de) | 1999-05-12 | 2004-06-24 | Yamasa Corp., Choshi | 4'-c-ethynyl-purin-nukleoside |
| AU1262001A (en) | 1999-11-04 | 2001-05-14 | Biochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| WO2001047833A1 (fr) | 1999-12-24 | 2001-07-05 | Asahi Glass Company, Limited | Filtre au nitrure de silicium et procede de fabrication correspondant |
| US6727267B2 (en) | 2000-04-05 | 2004-04-27 | Tularik Inc. | NS5B HVC polymerase inhibitors |
| EP1292310A1 (en) | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| WO2002005787A1 (fr) | 2000-07-17 | 2002-01-24 | Takeda Chemical Industries, Ltd. | Fabrication pour produits lyophilises |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| CA2434386C (en) | 2001-01-22 | 2006-12-05 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| US6677120B2 (en) | 2001-03-30 | 2004-01-13 | Isis Pharmaceuticals, Inc. | Building blocks for the solution phase synthesis of oligonucleotides |
| KR100798579B1 (ko) | 2001-03-31 | 2008-01-28 | 동화약품공업주식회사 | 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| BR0210357A (pt) | 2001-06-11 | 2004-06-29 | Shire Biochem Inc | Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US6899700B2 (en) | 2001-08-29 | 2005-05-31 | Kimberly-Clark Worldwide, Inc. | Therapeutic agent delivery tampon |
| WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| WO2003037262A2 (en) | 2001-10-29 | 2003-05-08 | Smithkline Beecham Corporation | Novel anit-infectives |
| AU2002365198A1 (en) | 2001-10-30 | 2003-07-30 | Smithkline Beecham Corporation | Novel anti-infectives |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| WO2003052248A1 (es) | 2001-12-18 | 2003-06-26 | Fernandez Del Castillo Y Simon | Multipiston en columna |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| AU2003248566A1 (en) | 2002-05-24 | 2003-12-12 | Smithkline Beecham Corporation | Novel anti-infectives |
| PL374792A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| US7456155B2 (en) | 2002-06-28 | 2008-11-25 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| PT1523489E (pt) | 2002-06-28 | 2014-06-24 | Centre Nat Rech Scient | Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| AU2003291670A1 (en) | 2002-11-01 | 2004-06-07 | Abbott Laboratories | Anti-infective agents |
| NO319194B1 (no) | 2002-11-14 | 2005-06-27 | Pronova Biocare As | Lipase-katalysert forestringsfremgangsmate av marine oljer |
| HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
| TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| TWI294882B (en) | 2002-12-09 | 2008-03-21 | Hoffmann La Roche | Anhydrous crystalline azido cytosine hemisulfate derivative |
| AU2003300956A1 (en) | 2002-12-11 | 2004-06-30 | Smithkline Beecham Corporation | Anti-infectives |
| WO2004052313A2 (en) | 2002-12-11 | 2004-06-24 | Smithkline Beecham Corporation | Anti-infectives |
| AU2003297235A1 (en) | 2002-12-17 | 2004-07-22 | Smithkline Beecham Corporation | Anti-infectives |
| US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| CA2528294A1 (en) | 2003-06-19 | 2005-01-06 | F. Hoffmann-La Roche Ag | Processes for preparing 4'-azido nucleoside derivatives |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| WO2005019191A2 (en) | 2003-08-25 | 2005-03-03 | Abbott Laboratories | 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c |
| JP4704342B2 (ja) | 2003-09-22 | 2011-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウイルスに対し活性な大環状ペプチド |
| AR047793A1 (es) | 2004-01-30 | 2006-02-22 | Medivir Ab | Inhibidores de la serina proteasa ns-3 del vhc |
| BRPI0514591A (pt) | 2004-08-23 | 2008-06-17 | Hoffmann La Roche | compostos antivirais heterocìclicos |
| CA2577526A1 (en) * | 2004-08-23 | 2006-03-02 | Joseph Armstrong Martin | Antiviral 4'-azido-nucleosides |
| ES2358853T3 (es) * | 2006-10-10 | 2011-05-16 | Medivir Ab | Inhibidor nucleosídico de vhc. |
-
2007
- 2007-10-04 ES ES07820934T patent/ES2358853T3/es active Active
- 2007-10-04 JP JP2009531813A patent/JP2010505902A/ja not_active Ceased
- 2007-10-04 CN CN201010274006XA patent/CN101979397B/zh not_active Expired - Fee Related
- 2007-10-04 AP AP2009004812A patent/AP2009004812A0/xx unknown
- 2007-10-04 EP EP07820934A patent/EP2084175B1/en active Active
- 2007-10-04 CN CN2007800379054A patent/CN101573370B/zh not_active Expired - Fee Related
- 2007-10-04 DK DK07820934.3T patent/DK2084175T3/da active
- 2007-10-04 BR BRPI0719258-4A2A patent/BRPI0719258A2/pt active Search and Examination
- 2007-10-04 AT AT07820934T patent/ATE493428T1/de active
- 2007-10-04 WO PCT/EP2007/060557 patent/WO2008043704A1/en active Application Filing
- 2007-10-04 EP EP10196341A patent/EP2361922B1/en active Active
- 2007-10-04 NZ NZ575889A patent/NZ575889A/en not_active IP Right Cessation
- 2007-10-04 MY MYPI20091428A patent/MY145314A/en unknown
- 2007-10-04 PT PT07820934T patent/PT2084175E/pt unknown
- 2007-10-04 KR KR1020097009591A patent/KR20090078347A/ko not_active Application Discontinuation
- 2007-10-04 AU AU2007306405A patent/AU2007306405A1/en not_active Abandoned
- 2007-10-04 PL PL07820934T patent/PL2084175T3/pl unknown
- 2007-10-04 SI SI200730544T patent/SI2084175T1/sl unknown
- 2007-10-04 RS RS20110127A patent/RS51643B/en unknown
- 2007-10-04 CA CA2665049A patent/CA2665049C/en not_active Expired - Fee Related
- 2007-10-04 EA EA200970358A patent/EA018935B1/ru not_active IP Right Cessation
- 2007-10-04 MX MX2009003452A patent/MX2009003452A/es active IP Right Grant
- 2007-10-04 PL PL10196341T patent/PL2361922T3/pl unknown
- 2007-10-04 DE DE602007011658T patent/DE602007011658D1/de active Active
- 2007-10-04 ES ES10196341T patent/ES2392948T3/es active Active
- 2007-10-10 US US11/973,681 patent/US7666856B2/en not_active Expired - Fee Related
-
2009
- 2009-03-31 GT GT200900069A patent/GT200900069A/es unknown
- 2009-03-31 CO CO09033094A patent/CO6180441A2/es not_active Application Discontinuation
- 2009-04-05 IL IL197907A patent/IL197907A0/en unknown
- 2009-04-09 ZA ZA200902496A patent/ZA200902496B/xx unknown
- 2009-04-13 HN HN2009000614A patent/HN2009000614A/es unknown
- 2009-05-11 CR CR10789A patent/CR10789A/es not_active Application Discontinuation
- 2009-05-11 NO NO20091834A patent/NO20091834L/no not_active Application Discontinuation
-
2010
- 2010-01-20 US US12/690,842 patent/US7825239B2/en not_active Expired - Fee Related
- 2010-01-29 HK HK10101044.2A patent/HK1137459A1/xx not_active IP Right Cessation
- 2010-09-24 US US12/890,538 patent/US7935681B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 HR HR20110193T patent/HRP20110193T1/hr unknown
- 2011-03-17 CY CY20111100298T patent/CY1111342T1/el unknown
- 2011-03-28 US US13/073,821 patent/US8158779B2/en not_active Expired - Fee Related
- 2011-07-29 JP JP2011167159A patent/JP2011246485A/ja not_active Ceased
- 2011-08-02 HK HK11108019.7A patent/HK1154247A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110193T1 (hr) | Inhibitor hcv nukleozida | |
| AU2018332540B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| JP2010505902A5 (hr) | ||
| ES2744587T3 (es) | Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral | |
| JP5578853B2 (ja) | ウイルス感染の治療のための化合物、及び医薬組成物 | |
| ES2745462T3 (es) | Composición que comprende un inhibidor de NS3 proteasa de VHC y un profármaco de fosforamidato de nucleósido de 2'-desoxi-2'fluoro-2'-C-metiluridina | |
| JP5951690B2 (ja) | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ | |
| ES2398684T3 (es) | Análogos de carbanucleósido para el tratamiento antiviral | |
| RU2012136379A (ru) | 4'-азидонуклеозиды, активные в отношении hcv | |
| AU2015238851A1 (en) | Methods and compounds for treating paramyxoviridae virus infections | |
| SG171596A1 (en) | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus | |
| WO2005020884A2 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
| HRP20151000T1 (hr) | Antivirusni spojevi | |
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| HRP20130971T1 (hr) | Inhibitori virusne polimeraze | |
| JP2011526893A (ja) | ウイルス感染の治療のための化合物、及び医薬組成物 | |
| HRP20100180T1 (hr) | Novi spoj piridazina i njegova primjena | |
| EA201370186A1 (ru) | 1-метилэтиловый сложный эфир n-[(2'r)-2'-дезокси-2'-фтор-2'-метил-p-фенил-5'-уридил]-l-аланина и способ его получения | |
| JP2013537905A5 (hr) | ||
| Zhou et al. | Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses | |
| US10307438B2 (en) | Methods of treating hepatitis E viral infection | |
| AU2014233579B2 (en) | Nucleoside phosphoramidate prodrugs | |
| RU2009128978A (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций | |
| WO2024076951A2 (en) | Antiviral prodrugs and formulations thereof | |
| CN103980332B (zh) | 2′-氟-2′-(氟甲基)-2′-脱氧核苷类化合物及其磷酸酯潜药 |